1. Home
  2. UCL vs ATOS Comparison

UCL vs ATOS Comparison

Compare UCL & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo uCloudlink Group Inc.

UCL

uCloudlink Group Inc.

HOLD

Current Price

$0.88

Market Cap

38.1M

ML Signal

HOLD

Logo Atossa Therapeutics Inc.

ATOS

Atossa Therapeutics Inc.

HOLD

Current Price

$2.49

Market Cap

36.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UCL
ATOS
Founded
2014
2009
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
38.1M
36.2M
IPO Year
2019
2010

Fundamental Metrics

Financial Performance
Metric
UCL
ATOS
Price
$0.88
$2.49
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$23.00
AVG Volume (30 Days)
7.1K
242.5K
Earning Date
05-20-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$1,758.00
Revenue This Year
$11.60
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$13.72
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.88
$0.53
52 Week High
$4.19
$7.56

Technical Indicators

Market Signals
Indicator
UCL
ATOS
Relative Strength Index (RSI) 40.76 45.85
Support Level $0.88 $0.58
Resistance Level $0.97 $2.60
Average True Range (ATR) 0.04 0.19
MACD 0.00 0.14
Stochastic Oscillator 21.80 89.70

Price Performance

Historical Comparison
UCL
ATOS

About UCL uCloudlink Group Inc.

Ucloudlink Group Inc is engaged in the provision of data connectivity services and sales of Wi-Fi terminals and data-related products globally. Its uCloudlink cloud SIM platform is designed for shared mobile data connectivity services by allocating the SIM cards remotely and dynamically to users. Ucloudlink's core business is to provide mobile data connectivity services at competitive prices, which it delivers through a range of hardware products and service solutions to its business partners, retail, and enterprise customers. The main hardware terminals offered by the company include portable Wi-Fi terminals, smartphones, and smart-hardware products for international and local mobile data connectivity services. Geographically, it generates maximum revenue from Japan.

About ATOS Atossa Therapeutics Inc.

Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.

Share on Social Networks: